General
Preferred name
cariprazine
Synonyms
CARIPRAZINE HYDROCHLORIDE ()
Cariprazine HCl ()
RGH188 hydrochloride ()
RGH-188 ()
cariprazine hydrochloride, prolonged-release ()
Cariprazine (hydrochloride) ()
RGH-188 HCL ()
VRAYLAR ()
Reagila ()
Fri-7000188 ()
MP-214 ()
Cariprazina ()
GED-129 ()
Cariprazine-d6 ()
P&D ID
PD009328
CAS
1083076-69-0
839712-12-8
1308278-67-2
Tags
available
drug
Approved by
FDA
First approval
2015
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
bipolar I disorder
Psychosis
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cariprazine hydrochloride is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
PRICE 44
INDICATION Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I; disorder.
TOXICITY Accidental acute overdosage (48 mg/day) was reported in one patient. This patient experienced orthostasis and sedation. The patient fully recovered the same day.; Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Cariprazine is not approved for the treatment of patients with dementia-related psychosis.
DESCRIPTION Cariprazine is an antipsychotic. Our structure was drawn from the INN record which shows stereo-chemistry for this compound. PubChem have a record only for the non-chiral molecule, with CID 11154555. The compound is liphophilic meaning that it can easily cross the blood-brain barrier, to reach its site of action . (GtoPdb)
PRICE 166
DESCRIPTION Cariprazine hydrochloride (RGH188 hydrochloride) is an antipsychotic drug, is a D3 and D2 receptor partial agonist((Ki of 0.085 nM and 0.49 nM, respectively) (TargetMol Bioactive Compound Library)
DESCRIPTION Cariprazine (RGH-188) is a novel antipsychotic drug candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM). (TargetMol Bioactive Compound Library)
Compound Sets
21
Cayman Chemical Bioactives
24025
31446
29449
ChEMBL Approved Drugs
CHEMBL2024517
CHEMBL2028019
ChEMBL Drugs
CHEMBL2024517
CHEMBL2028019
Concise Guide to Pharmacology 2023/24
7671
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06016
DrugBank Approved Drugs
DB06016
DrugCentral
5037
DrugCentral Approved Drugs
5037
EU-OPENSCREEN Bioactive Compound Library
EOS101463
EUbOPEN Chemogenomics Library
EUB0000493
Guide to Pharmacology
7671
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL2024517
CHEMBL2028019
Mcule NIBR MoA Box Subset
MCULE-4553436779
MedChem Express Bioactive Compound Library
HY-14763A
HY-14763
NCATS Inxight Approved Drugs
F6RJL8B278
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
cariprazine-rgh-188
TargetMol Bioactive Compound Library
T8382
T4577
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
426.2
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
1
cLogP
4.34
TPSA
38.82
Fraction CSP3
0.67
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
D2
D3
dopamine
5-HT1A
DRD2, DRD3
MOA
Dopamine Receptor
Dopamine D2/3 receptor partial agonist
Dopamine Receptor antagonist
Member status
member
Indication
schizophrenia
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Recommended Cell Concentration
10 nM
Source data